Cmd1 Enzyme Catalyzes Glyceryl Group Transfer to 5mC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of 5-methylcytosine (5mC) derivatization modifications in organisms is limited, and the enzymatic activities and new functions of Tet homologous proteins, such as those found in Chlamydomonas reinhardtii, require further study to explore their potential applications.
Innovation Solution
A method involving the use of a Cmd1 enzyme to add a glyceryl group to the methyl group of 5-methylcytosine (5mC) in methylated nucleic acids, utilizing vitamin C or its analogues as a glyceryl group donor, and ferrous ions as a cofactor, to create novel modifications that can be used for therapeutic and diagnostic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If Tet homologous proteins are studied to understand 5mC derivatization, then new enzymatic functions may be discovered, but the complexity of enzymatic activity characterization increases
Solution Approach 1:
The patent applies parameter changes by systematically varying reaction conditions (substrate concentration, pH, temperature, cofactor presence) to characterize the enzymatic activity of Cmd1. This allows the complex enzymatic function to be broken down into measurable parameters, making the characterization manageable while still discovering the novel glyceryl group transfer function.
Solution Approach 2:
The patent uses vitamin C (ascorbic acid) as an intermediary substance that donates glyceryl groups to 5mC. This intermediary simplifies the reaction system by providing a clear substrate for the enzymatic action, making it easier to characterize the enzyme's specific activity while still achieving the discovery of its novel function.
2Reliability
If new 5mC modifications are created for therapeutic applications, then treatment effectiveness may improve, but the complexity of developing therapeutic methods increases
Solution Approach 1:
The patent applies preliminary action by first characterizing the enzymatic activity of Cmd1 in vitro under controlled conditions, establishing the biochemical basis for therapeutic application. This preliminary characterization work is completed before moving to therapeutic development, ensuring that the enzyme's specific activity and substrate requirements are well-understood, thereby simplifying the subsequent therapeutic method development.
Solution Approach 2:
The patent suggests that the Cmd1 enzyme system may utilize endogenous vitamin C pools within cells to provide glyceryl groups for 5mC modification. This self-service mechanism reduces the need for external intervention or complex delivery systems, thereby simplifying therapeutic development while maintaining reliable modification of target genes.
3Adaptability or versatility
IfCmd1 enzyme is used to add glyceryl groups to 5mC, then novel nucleic acid modifications are achieved, but the difficulty of detecting and measuring these modifications increases
Solution Approach 1:
The patent applies color changes by utilizing the redox-active nature of vitamin C and its oxidation products in the reaction system. The enzymatic reaction involves oxidation-reduction processes that can be monitored through color changes, providing a direct visual and quantitative measure of the modification process, thereby simplifying detection.
Solution Approach 2:
The patent implements feedback mechanisms by monitoring the reaction progress through measurement of substrate consumption and product formation. This feedback allows real-time assessment of the enzymatic activity and modification extent, simplifying the detection and measurement process while maintaining control over the modification process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection and modification of 5mC, allowing for targeted regulation of gene expression and epigenetic changes, enhancing our ability to understand and manipulate nucleic acid modifications, and providing a new avenue for therapeutic interventions.
Implementation Method 1
treating the methylated nucleic acid with a Cmd1 enzyme, so that the glyceryl group is added to the methyl group of 5-methylcytosine (5mC) of the methylated nucleic acid
Implementation Method 2
adding a glyceryl group to a methyl group of 5-methylcytosine (5mC) of a methylated nucleic acid
Implementation Method 3
a ferrous ion (Fe2+) is present as a cofactor
Implementation Method 4
the glyceryl group-containing compound is vitamin C or its analogue
Data Source
AI summary
The present invention relates to a novel modification of a 5-methylcytosine nucleic acid catalyzed by a Cmd1 enzyme and an application thereof. The present inventors have for the first time discovered Cmd1, a 5mC-modifying enzyme, which can link a glyceryl group to a 5mC methyl carbon of a methylated nucleic acid through a carbon-carbon single bond, and this is a new epigenetic modification.